鼻咽癌根治性放疗后放射性舌下神经麻痹:临床预测因素与剂量-毒性关系
高放疗剂量、病前糖尿病、晚期T分期及影像学舌下神经管受累为独立临床危险因素,D1cc是8年时最佳预测指标(AUC=0.826)。D1cc<74 Gy EQD2者麻痹风险显著低于≥74 Gy EQD2者(2.4% vs 20.8%,p<0.001)。
要点
- D1cc<74 Gy EQD2可作为剂量约束,使8年麻痹风险<5%。
- 高剂量、糖尿病、晚期T分期及舌下神经管受累为独立危险因素。
核心结论
- 鼻咽癌根治性IMRT后放射性舌下神经麻痹发生率较高,D1cc<74 Gy EQD2可作为放疗计划中的有用剂量约束,以将8年麻痹风险限制在<5%。
研究设计与样本
- 回顾性研究纳入2003—2011年接受根治性IMRT的797例鼻咽癌患者,中位随访8.1年,回顾性勾画330条独立舌下神经并按标准化图谱执行。
主要发现
- 高放疗剂量、病前糖尿病、晚期T分期及影像学舌下神经管受累为独立临床危险因素。
- D1cc是IMRT后8年发生放射性神经麻痹的最佳预测指标(AUC=0.826)。
- D1cc为74 Gy EQD2的舌下神经估计麻痹风险为4.7%。
- D1cc<74 Gy EQD2的神经麻痹风险显著低于≥74 Gy EQD2者(2.4% vs 20.8%,p<0.001)。
关键数值与推荐
- D1cc<74 Gy EQD2可作为剂量约束,使8年麻痹风险<5%。
- D1cc为74 Gy EQD2时估计麻痹风险为4.7%。
- D1cc<74 Gy EQD2与≥74 Gy EQD2的麻痹风险分别为2.4%与20.8%(p<0.001)。
临床怎么用
- 在鼻咽癌IMRT计划设计中将舌下神经D1cc限制在<74 Gy EQD2,以降低8年放射性舌下神经麻痹风险至<5%。
- 对合并糖尿病、晚期T分期或影像学舌下神经管受累的高危患者,应重点关注舌下神经剂量约束。
局限性
- 本研究为回顾性研究,舌下神经勾画为回顾性完成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Radiation-induced hypoglossal nerve palsy is a debilitating and irreversible late complication after definitive radiotherapy for nasopharyngeal carcinoma (NPC) and other skull base tumors. This study sets to evaluate its incidence and clinical predictive factors, and to propose relevant dosimetric constraints for this structure to guide radiotherapy planning. MATERIALS AND METHODS: We undertook a retrospective review of 797 NPC patients who underwent definitive intensity-modulated radiotherapy (IMRT) between 2003 and 2011. Cumulative incidence and clinical predictors for radiation-induced hypoglossal nerve palsy were evaluated. Archived radiotherapy plans were retrieved and 330 independent hypoglossal nerves were retrospectively contoured following standardized atlas. Optimal threshold analyses of dosimetric parameters (Dmax, D0.5cc, D1cc, D2cc, Dmean) were conducted using receiver operating characteristic curves. Normal tissue complication probability was generated with logistic regression modeling. RESULTS: With a median follow-up of 8.1 years, sixty-nine (8.7%) patients developed radiation-induced hypoglossal nerve palsy. High radiotherapy dose, premorbid diabetes, advanced T-stage and radiological hypoglossal canal involvement were independent clinical risk factors. Maximum dose received by 1 cc volume (D1cc) was the best predictor for the development of radiation-induced nerve palsy (AUC = 0.826) at 8 years after IMRT. Hypoglossal nerves with D1cc of 74 Gy EQD2 had an estimated palsy risk of 4.7%. Nerves with D1cc <74 Gy EQD2 had significantly lower risk of palsy than those ≥74 Gy EQD2 (2.4% vs 20.8%, p <0.001). CONCLUSION: Incidence of radiation-induced hypoglossal nerve palsy was high after definitive IMRT for NPC. D1cc <74 Gy EQD2 can serve as a useful dose constraint to adopt during radiotherapy planning to limit palsy risk to <5% at 8 years after IMRT.
引用
- Chow JCH, Cheung KM, Au KH, et al. Radiation-induced hypoglossal nerve palsy after definitive radiotherapy for nasopharyngeal carcinoma: Clinical predictors and dose-toxicity relationship. Radiother Oncol. 2019. PMID: 31252300. doi:10.1016/j.radonc.2019.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。